Lingo is Abbott’s over-the-counter continuous glucose monitor (CGM) for nondiabetic people. Withings users will also be able ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

The ‍guidance, along with comments from ​FDA Commissioner Marty Makary, adds to existing policy that classifies low-risk ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical ...

Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by ...

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A ...

Medtronic disclosed Diabetes unit executive pay packages for 2025 and compensation targets for when they'll lead MiniMed as a ...

"We're not sure exactly on the timeline, but yeah we won't be seeing him over the next couple of weeks." #URC #ULSvMUN ...

Hunterbrook Capital gained 23% after fees last year through September, above the S&P 500’s roughly 15% return over the same ...

The U.S. Food and Drug Administration (FDA) announced on Tuesday that it will limit regulatory oversight of wearable devices ...

Abbott (NYSE:ABT) today unveiled a new feature within its FreeStyle Libre app for continuous glucose monitoring (CGM).

FDA announces wearable devices providing non-medical info won't face regulation, offering clarity on digital health ...